DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Cyclophosphamide (Cyclophosphamide) - Disability - Suspected Cause - Side Effect Reports

 
 



Index of reports > Disability (128)

Below is the selection of side effect reports (a.k.a. adverse event reports) related to Cyclophosphamide disability. The selected reports were submitted to the FDA during the sample period of about a year.

 Reports 1 - 30 of 128   Next >>

Possible Cyclophosphamide side effects in female

Reported by a physician from Canada on 2012-08-13

Patient: female

Reactions: Oral Herpes

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Prednisolone
    Dosage: dose of last drug taken:100mg, date of recent dose taken prior to onset of ae:17/jun/2012
    Administration route: Oral
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-04-10

Vincristine
    Dosage: route:intravenous push, dose of last drug taken:2mg, date of last dose taken prior to onset of ae:13
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-04-10

Doxorubicin Hydrochloride
    Dosage: dose of last drug taken:91mg, date of last dose taken prior to onset of ae:13/jun/2012
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-04-10

Mabthera
    Dosage: volume of last drug taken:343.5ml, dose concentration of last drug taken:1.99mg/ml, date of last do
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-04-10

Cyclophosphamide
    Dosage: dose of last drug taken:1370mg, date of last dose taken prior to onset of ae:13/jun/2012
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-04-10

Other drugs received by patient: Colace; Polyethylene Glycol; Tramadol Hydrochloride and Acetaminophen; Senokot; Valacyclovir Hydrochloride; Codeine; Benzydamine; Naproxen; Morphine; Preparation H Cream; Lidocaine; Valacyclovir Hydrochloride; Ranitidine; YAZ; Morphine; Pantoprazole; Acetaminophen; Diphenhydramine Hydrochloride; Suppository (Unk Ingredients)



Possible Cyclophosphamide side effects in male

Reported by a physician from Japan on 2012-08-09

Patient: male, weighing 57.0 kg (125.4 pounds)

Reactions: Cytomegalovirus Hepatitis, Cytomegalovirus Enterocolitis, Cytomegalovirus Chorioretinitis, Pancytopenia

Adverse event resulted in: life threatening event, hospitalization, disablity

Drug(s) suspected as cause:
Cyclosporine
    Administration route: Oral
    Indication: Histiocytosis Haematophagic
    Start date: 2011-09-26

Rituximab
    Indication: Histiocytosis Haematophagic
    Start date: 2011-04-13

Rituximab
    Dosage: cycle 3 % 4
    Indication: B-Cell Lymphoma
    Start date: 2011-05-25

Vincristine Sulfate
    Indication: Histiocytosis Haematophagic

Vincristine Sulfate
    Dosage: 2 milligram daily;
    Indication: B-Cell Lymphoma
    Start date: 2011-09-27

Prednisolone
    Dosage: 60 milligram daily;
    Administration route: Oral
    Indication: B-Cell Lymphoma
    Start date: 2011-09-09
    End date: 2011-10-17

Treanda
    Indication: B-Cell Lymphoma
    Start date: 2011-04-13

Cyclophosphamide
    Indication: Histiocytosis Haematophagic

Prednisolone
    Indication: Histiocytosis Haematophagic

Etoposide
    Indication: Histiocytosis Haematophagic
    Start date: 2011-09-13

Cyclophosphamide
    Dosage: 1200 milligram daily;
    Indication: B-Cell Lymphoma
    Start date: 2011-09-27
    End date: 2011-10-17

Doxorubicin HCL
    Indication: Histiocytosis Haematophagic
    Start date: 2011-09-27

Other drugs received by patient: Pirarubicin Hydrochloride



Possible Cyclophosphamide side effects in female

Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2012-08-01

Patient: female

Reactions: Gait Disturbance, Myelopathy

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Vincristine Sulfate
    Indication: Burkitt's Lymphoma

Doxorubicin Hydrochloride
    Indication: Burkitt's Lymphoma

Cyclophosphamide
    Indication: Burkitt's Lymphoma

(Mabthera)
    Dosage: intravenous drip
    Indication: Burkitt's Lymphoma

Prednisone
    Indication: Burkitt's Lymphoma



Possible Cyclophosphamide side effects in female

Reported by a physician from United Kingdom on 2012-07-27

Patient: female

Reactions: Myelopathy

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Mabthera
    Indication: Burkitt's Lymphoma

Doxorubicin Hydrochloride
    Indication: Burkitt's Lymphoma

Vincristine
    Indication: Burkitt's Lymphoma

Prednisone
    Indication: Burkitt's Lymphoma

Cyclophosphamide
    Indication: Burkitt's Lymphoma



Possible Cyclophosphamide side effects in 33 year old female

Reported by a pharmacist from Japan on 2012-07-27

Patient: 33 year old female

Reactions: Cystitis Haemorrhagic, Shock Haemorrhagic

Adverse event resulted in: hospitalization, disablity

Drug(s) suspected as cause:
Cyclophosphamide
    Administration route: Oral
    Indication: Breast Cancer
    Start date: 2008-09-01
    End date: 2011-08-01

Halaven
    Indication: Breast Cancer
    Start date: 2011-09-12
    End date: 2011-10-31



Possible Cyclophosphamide side effects in female

Reported by a physician from United Kingdom on 2012-07-27

Patient: female

Reactions: Abasia, Myelopathy

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Mabthera
    Dosage: unk
    Indication: Burkitt's Lymphoma

Vincristine
    Dosage: unk
    Indication: Product Used FOR Unknown Indication

Doxorubicin HCL
    Dosage: unk

Prednisone TAB
    Dosage: unk
    Indication: Product Used FOR Unknown Indication

Cyclophosphamide
    Dosage: unk



Possible Cyclophosphamide side effects in female

Reported by a lawyer from France on 2012-07-27

Patient: female

Reactions: Cardiomyopathy

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 6 cycles
    Indication: Breast Cancer
    Start date: 2004-07-15
    End date: 2004-11-05

Fluorouracil
    Dosage: 6 cycles
    Indication: Breast Cancer
    Start date: 2004-07-15
    End date: 2004-11-05

Epirubicin Hydrochloride
    Dosage: 6 cycles
    Indication: Breast Cancer
    Start date: 2004-07-15
    End date: 2004-11-05

Other drugs received by patient: Levothyroxine Sodium; Tamoxifen Citrate; Levothyroxine Sodium; Lipanthyl 160; Aromasin



Possible Cyclophosphamide side effects in 42 year old female

Reported by a physician from United Kingdom on 2012-07-27

Patient: 42 year old female, weighing 91.0 kg (200.2 pounds)

Reactions: Sinus Headache

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Cyclophosphamide



Possible Cyclophosphamide side effects in female

Reported by a physician from United Kingdom on 2012-07-23

Patient: female

Reactions: Abasia, Myelopathy

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Prednisone

Doxorubicin Hydrochloride

Vincristine

Mabthera
    Indication: Burkitt's Lymphoma

Cyclophosphamide



Possible Cyclophosphamide side effects in 65 year old male

Reported by a health professional (non-physician/pharmacist) from Germany on 2012-07-19

Patient: 65 year old male, weighing 82.0 kg (180.4 pounds)

Reactions: Arrhythmia Supraventricular, Incontinence, JC Virus Infection, Hemiparesis, Somnolence, Progressive Multifocal Leukoencephalopathy, Blindness, Demyelination

Adverse event resulted in: death, hospitalization, disablity

Drug(s) suspected as cause:
Rituximab (Rituximab)
    Dosage: 500 mg/m^2; day 14
    Indication: Chronic Lymphocytic Leukaemia

Cyclophosphamide
    Dosage: 150 mg/m^2; day 1-3
    Indication: Chronic Lymphocytic Leukaemia

Fludarabine Phosphate
    Dosage: 20 mg/m^2; day 1-3
    Indication: Chronic Lymphocytic Leukaemia

Other drugs received by patient: Chlorambucil; Flecainide Acetate



Possible Cyclophosphamide side effects in female

Reported by a health professional (non-physician/pharmacist) from France on 2012-07-17

Patient: female

Reactions: Palmar-Plantar Erythrodysaesthesia Syndrome, Paraesthesia

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Doxorubicin HCL
    Start date: 2012-05-24

Cyclophosphamide
    Start date: 2012-05-10

Vincristine
    Start date: 2012-05-10

Cyclophosphamide
    Start date: 2012-05-24
    End date: 2012-05-24

Vincristine
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26
    End date: 2012-05-10

Cyclophosphamide
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26
    End date: 2012-05-24

Doxorubicin HCL
    Start date: 2012-05-10

Vincristine
    Start date: 2012-05-24
    End date: 2012-05-24

Doxorubicin HCL
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26
    End date: 2012-05-24

Other drugs received by patient: Rituximab; Prednisone; Prednisone; Prednisone; Rituximab; Rituximab



Possible Cyclophosphamide side effects in female

Reported by a physician from United Kingdom on 2012-07-16

Patient: female

Reactions: Abasia, Myelopathy

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Doxorubicin HCL
    Indication: Product Used FOR Unknown Indication

Vincristine
    Indication: Product Used FOR Unknown Indication

Mabthera
    Indication: Burkitt's Lymphoma

Prednisone
    Indication: Product Used FOR Unknown Indication

Cyclophosphamide
    Indication: Product Used FOR Unknown Indication



Possible Cyclophosphamide side effects in 28 year old female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-11

Patient: 28 year old female

Reactions: Streptococcal Bacteraemia, Vomiting, Nausea, Peripheral Sensorimotor Neuropathy, Carbon Monoxide Diffusing Capacity Decreased, Pancytopenia, Febrile Neutropenia, Hypoaesthesia, Paraesthesia, Gait Disturbance, Coordination Abnormal, Renal Failure Acute

Adverse event resulted in: hospitalization, disablity

Drug(s) suspected as cause:
Cisplatin
    Dosage: 45 mg/m2, unk

Bleomycin Sulfate
    Dosage: 15 units/m2 over 24h on day2

Etoposide
    Dosage: 200 mg/m2, over 2h on day3
    Indication: Ovarian Cancer

Cyclophosphamide
    Dosage: 750 mg/m2, unk

Cisplatin
    Dosage: 90 mg/m2, over 4h on day1
    Indication: Ovarian Cancer

Doxorubicin HCL
    Dosage: 30 mg/m2, unk

Etoposide
    Dosage: 100 mg/m2, unk

Cyclophosphamide
    Dosage: 1000 mg/m2, over 60min on day 2
    Indication: Ovarian Cancer

Doxorubicin HCL
    Dosage: 45 mg/m2, over 30min on day3
    Indication: Ovarian Cancer

Vinblastine
    Dosage: 6 mg/m2, over 30 minutes on day 1
    Indication: Ovarian Cancer

Other drugs received by patient: Pegfilgrastim



Possible Cyclophosphamide side effects in female

Reported by a physician from Canada on 2012-07-10

Patient: female

Reactions: Stomatitis, LIP Ulceration

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Prednisolone
    Dosage: dose of last drug taken:100mg, date of recent dose taken prior to onset of ae:17/jun/2012
    Administration route: Oral
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-04-10

Cyclophosphamide
    Dosage: dose of last drug taken:1370mg, date of last dose taken prior to onset of ae:13/jun/2012
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-04-10

Vincristine Sulfate
    Dosage: route:intravenous push, dose of last drug taken:2mg, date of last dose taken prior to onset of ae:13
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-04-10

Mabthera
    Dosage: volume of last drug taken:343.5ml, dose concentration of last drug taken:1.99mg/ml, date of last do
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-04-10

Doxorubicin Hydrochloride
    Dosage: dose of last drug taken:91mg, date of last dose taken prior to onset of ae:13/jun/2012
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-04-10



Possible Cyclophosphamide side effects in female

Reported by a health professional (non-physician/pharmacist) from France on 2012-07-03

Patient: female

Reactions: Palmar-Plantar Erythrodysaesthesia Syndrome

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Cyclophosphamide
    Start date: 2012-05-10

Cyclophosphamide
    Start date: 2012-05-24

Doxorubicin HCL
    Start date: 2012-05-24

Vincristine
    Start date: 2012-05-10

Vincristine
    Start date: 2012-05-24

Rituxan
    Start date: 2012-05-24

Cyclophosphamide
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Doxorubicin HCL
    Start date: 2012-05-10

Vincristine
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Rituxan
    Start date: 2012-05-10

Prednisone
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Rituxan
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Prednisone
    Start date: 2012-05-10

Doxorubicin HCL
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Prednisone
    Start date: 2012-05-24



Possible Cyclophosphamide side effects in 62 year old female

Reported by a health professional (non-physician/pharmacist) from Switzerland on 2012-06-30

Patient: 62 year old female

Reactions: Off Label Use, JC Virus Infection, Progressive Multifocal Leukoencephalopathy

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Prednisone TAB
    Dosage: 8 cycles
    Indication: Hodgkin's Disease Recurrent

Etoposide
    Indication: Hodgkin's Disease Recurrent

Procarbazine Hydrochloride
    Dosage: 8 cycles
    Indication: Hodgkin's Disease Recurrent

Doxorubicin HCL
    Dosage: 8 cycles
    Indication: Hodgkin's Disease Recurrent

Vincristine
    Dosage: 8 cycles
    Indication: Hodgkin's Disease Recurrent

Cyclophosphamide
    Dosage: 8 cycles
    Indication: Hodgkin's Disease Recurrent

Bleomycin Sulfate
    Dosage: 8 cycles
    Indication: Hodgkin's Disease Recurrent



Possible Cyclophosphamide side effects in 28 year old female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-29

Patient: 28 year old female

Reactions: Streptococcal Bacteraemia, Vomiting, Nausea, Peripheral Sensorimotor Neuropathy, Carbon Monoxide Diffusing Capacity Decreased, Pancytopenia, Febrile Neutropenia, Hypoaesthesia, Paraesthesia, Coordination Abnormal, Gait Disturbance, Renal Failure Acute

Adverse event resulted in: hospitalization, disablity

Drug(s) suspected as cause:
Cisplatin
    Dosage: 90 mg/m2 over 4h on day1
    Indication: Ovarian Cancer

Cisplatin
    Dosage: 45 mg/m 2

Etoposide
    Dosage: 200 mg/m2 over 2h on day3
    Indication: Ovarian Cancer

Cyclophosphamide
    Dosage: 1000 mg/m2 over 60min on day 2
    Indication: Ovarian Cancer

Bleomycin
    Dosage: 15 units/m2 over 24h on day2

Doxorubicin HCL
    Dosage: 45 mg/m2 over 30min on day3
    Indication: Ovarian Cancer

Etoposide
    Dosage: 100 mg/m 2

Cyclophosphamide
    Dosage: 750 mg/m 2

Doxorubicin HCL
    Dosage: 30 mg/m 2

Vinblastine
    Dosage: 6mg/m2 over 30min on day1
    Indication: Ovarian Cancer

Other drugs received by patient: Pegfilgrastim



Possible Cyclophosphamide side effects in 58 year old female

Reported by a health professional (non-physician/pharmacist) from France on 2012-06-29

Patient: 58 year old female

Reactions: Cardiac Failure, Mitral Valve Incompetence, Systolic Dysfunction

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 500 mg/m2, cyclic
    Indication: Breast Cancer
    Start date: 2002-02-25
    End date: 2002-06-17

Fluorouracil
    Dosage: 500 mg/m2, cyclic
    Indication: Breast Cancer
    Start date: 2002-02-25
    End date: 2002-06-17

Epirubicin Hydrochloride
    Dosage: 100 mg/m2, cyclic
    Indication: Breast Cancer
    Start date: 2002-02-25
    End date: 2002-06-17



Possible Cyclophosphamide side effects in male

Reported by a physician from France on 2012-06-27

Patient: male, weighing 103.0 kg (226.6 pounds)

Reactions: Cerebral Ischaemia

Adverse event resulted in: hospitalization, disablity

Drug(s) suspected as cause:
Plavix
    Administration route: Oral
    Start date: 2011-04-28

Cyclophosphamide
    Start date: 2011-06-23
    End date: 2011-08-22

Fludarabine Phosphate
    Start date: 2011-06-23
    End date: 2011-08-22

NO Drug Administered (Rituximab)
    Indication: Chronic Lymphocytic Leukaemia

Other drugs received by patient: Aspirin; Phenoxymethyl Penicillin; Nitroglycerin; Novorapid; Digoxin; Nebivolol HCL; Lantus; Pentoxifylline; Atorvastatin; Lercanidipine; Lantus; Nebivolol HCL; Amaryl



Possible Cyclophosphamide side effects in female

Reported by a lawyer from France on 2012-06-22

Patient: female

Reactions: Cardiomyopathy

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 6 cycles
    Indication: Breast Cancer
    Start date: 2004-07-15

Fluorouracil
    Dosage: 6 cycles
    Indication: Breast Cancer
    Start date: 2004-07-15

Epirubicin Hydrochloride
    Dosage: 6 cycles
    Indication: Breast Cancer
    Start date: 2004-07-15

Other drugs received by patient: Levothyroxine Sodium



Possible Cyclophosphamide side effects in female

Reported by a health professional (non-physician/pharmacist) from France on 2012-06-21

Patient: female

Reactions: Cardiac Failure, Mitral Valve Incompetence, Systolic Dysfunction

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Cyclophosphamide
    Start date: 2002-02-25
    End date: 2002-06-17

Fluorouracil
    Start date: 2002-02-25
    End date: 2002-06-17

Epirubicin Hydrochloride
    Start date: 2002-02-25
    End date: 2002-06-17



Possible Cyclophosphamide side effects in female

Reported by a individual with unspecified qualification from Denmark on 2012-06-15

Patient: female

Reactions: Thrombosis, Pain in Extremity, Thrombectomy, LEG Amputation

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Epirubicin
    Indication: Breast Cancer
    Start date: 2010-12-07

Cyclophosphamide
    Indication: Breast Cancer
    Start date: 2010-12-07

Taxotere
    Indication: Breast Cancer
    Start date: 2010-12-07

Other drugs received by patient: Clemastine Fumarate



Possible Cyclophosphamide side effects in female

Reported by a physician from Finland on 2012-05-31

Patient: female

Reactions: Progressive Multifocal Leukoencephalopathy

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Mabthera
    Dosage: frequency: two infusions
    Indication: Lupus Vasculitis
    Start date: 2009-11-11
    End date: 2009-12-29

Cyclophosphamide
    Dosage: six 1000 mg cycles
    Indication: Lupus Vasculitis
    Start date: 2009-05-26
    End date: 2009-10-21

Other drugs received by patient: Cortisone Acetate



Possible Cyclophosphamide side effects in 35 year old male

Reported by a physician from Israel on 2012-05-29

Patient: 35 year old male

Reactions: Respiratory Disorder

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Doxorubicin HCL
    Dosage: 25 mg/m2, m2for 2 cycles of standard beacopp
    Indication: Hodgkin's Disease

Etoposide
    Dosage: 300 mg/m2, for 2 cycles of standard beacopp
    Indication: Hodgkin's Disease

Cyclophosphamide
    Dosage: 650 mg/m2for 2 cycles of standard beacopp
    Indication: Hodgkin's Disease

Etoposide
    Dosage: 600 mg/m2, for 4 cycles of escalated beacopp

Vincristine
    Dosage: 1.4 mg/m2, for all 6 cycles of beacopp
    Indication: Hodgkin's Disease

Procarbazine
    Dosage: 700 mg/m2, for all 6 cycles of beacopp
    Indication: Hodgkin's Disease

Cyclophosphamide
    Dosage: 1250 mg/m2 for 4 cycles of escalated beacopp

Bleomycin
    Dosage: 10 mg/m2, for all 6 cycles of beacopp
    Indication: Hodgkin's Disease

Prednisone TAB
    Dosage: 280 mg/m2,for all 6 cycles of beacopp
    Indication: Hodgkin's Disease

Doxorubicin HCL
    Dosage: 35 mg/m2, for 4 cycles of escalated beacopp



Possible Cyclophosphamide side effects in 46 year old female

Reported by a physician from Israel on 2012-05-29

Patient: 46 year old female

Reactions: Respiratory Disorder

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Etoposide
    Dosage: 300 mg/m2, for 6 cycles
    Indication: Hodgkin's Disease

Prednisone TAB
    Dosage: 280 mg/m2, for 6 cycles

Bleomycin Sulfate
    Dosage: 10 mg/m2, for 6 cycles
    Indication: Hodgkin's Disease

Cyclophosphamide
    Dosage: 650 mg/m2, for 6 cycles
    Indication: Hodgkin's Disease

Doxorubicin HCL
    Dosage: 25 mg/m2, for 6 cycles
    Indication: Hodgkin's Disease

Procarbazine
    Dosage: 700 mg/m2, for 6 cycles
    Indication: Hodgkin's Disease

Vincristine
    Dosage: 1.4 mg/m2, for 6 cycles
    Indication: Hodgkin's Disease



Possible Cyclophosphamide side effects in 45 year old female

Reported by a physician from Israel on 2012-05-25

Patient: 45 year old female

Reactions: Respiratory Disorder

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Doxorubicin HCL
    Dosage: 25 mg/m2, for 6 cycles
    Indication: Hodgkin's Disease

Etoposide
    Dosage: 300 mg/m2, for 6 cycles
    Indication: Hodgkin's Disease

Bleomycin
    Dosage: 10 mg/m2, for 6 cycles
    Indication: Hodgkin's Disease

Cyclophosphamide
    Dosage: 650 mg/m2, for 6 cycles
    Indication: Hodgkin's Disease

Procarbazine Hydrochloride
    Dosage: 700 mg/m2, for 6 cycles
    Indication: Hodgkin's Disease

Vincristine
    Dosage: 1.4 mg/m2, for 6 cycles
    Indication: Hodgkin's Disease

Prednisone TAB
    Dosage: 280 mg/m2, for 6 cycles
    Indication: Hodgkin's Disease



Possible Cyclophosphamide side effects in female

Reported by a physician from United States on 2012-05-25

Patient: female

Reactions: Lung Consolidation, Osteonecrosis, Joint Range of Motion Decreased, Arthralgia, Limb Asymmetry, Gait Disturbance

Adverse event resulted in: hospitalization, disablity

Drug(s) suspected as cause:
Cytarabine
    Dosage: intrathecal
    Indication: Acute Lymphocytic Leukaemia

Daunorubicin HCL
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin HCL
    Indication: Acute Lymphocytic Leukaemia

Cyclophosphamide
    Indication: Acute Lymphocytic Leukaemia

Mercaptopurine
    Indication: Acute Lymphocytic Leukaemia

Vincristine Sulfate
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Dosage: intrathecal
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: intrathecal
    Indication: Acute Lymphocytic Leukaemia

Oncaspar
    Indication: Acute Lymphocytic Leukaemia

Thioguanine
    Indication: Acute Lymphocytic Leukaemia



Possible Cyclophosphamide side effects in female

Reported by a health professional (non-physician/pharmacist) from France on 2012-05-24

Patient: female

Reactions: Paraesthesia

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Doxorubicin HCL
    Start date: 2010-05-20
    End date: 2010-08-12

Vincristine
    Start date: 2010-09-02
    End date: 2010-10-14

Cyclophosphamide
    Start date: 2010-05-20
    End date: 2010-08-12

Cyclophosphamide
    Start date: 2010-09-02
    End date: 2010-10-14

Doxorubicin HCL
    Start date: 2010-09-02
    End date: 2010-10-14

Vincristine
    Start date: 2010-05-20
    End date: 2010-08-12

Other drugs received by patient: Prednisone TAB; Prednisone TAB



Possible Cyclophosphamide side effects in female

Reported by a individual with unspecified qualification from Japan on 2012-05-23

Patient: female

Reactions: Uterine Cancer, Urinary Tract Infection, Anaemia, Meningitis Bacterial, Leukoencephalopathy, Liver Disorder

Adverse event resulted in: hospitalization, disablity

Drug(s) suspected as cause:
Xeloda
    Administration route: Oral
    Indication: Breast Cancer Metastatic
    Start date: 2007-08-01
    End date: 2010-12-12

Cefpirome Sulfate
    Indication: Product Used FOR Unknown Indication
    Start date: 2010-12-13
    End date: 2010-12-20

Cyclophosphamide
    Administration route: Oral
    Indication: Product Used FOR Unknown Indication
    Start date: 2010-02-01
    End date: 2010-12-12

Cefpirome Sulfate
    Administration route: Oral
    End date: 2010-12-12

Other drugs received by patient: Mucosta; Tocopherol Concentrate CAP; Celestamine TAB; Meloxicam; Hirudoid; Cyclophosphamide; Neurovitan (Ukraine); Atines



Possible Cyclophosphamide side effects in 27 year old male

Reported by a physician from Israel on 2012-05-23

Patient: 27 year old male

Reactions: Respiratory Disorder

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Etoposide
    Dosage: 600 mg/m2,for 2 cycles of escalated beacopp

Vincristine
    Dosage: 1.4 mg/m2, for all 6 cycles of beacopp
    Indication: Hodgkin's Disease

Cyclophosphamide
    Dosage: 1250 mg/m2, for 2 cycles of escalated beacopp

Prednisone TAB
    Dosage: 280 mg/m2, for all 6 cycles of beacopp
    Indication: Hodgkin's Disease

Etoposide
    Dosage: 300 mg/m2, for 4 cycles of standard beacopp
    Indication: Hodgkin's Disease

Bleomycin Sulfate
    Dosage: 10 mg/m2, for all 6 cycles of beacopp
    Indication: Hodgkin's Disease

Cyclophosphamide
    Dosage: 650 mg/m2,for 4 cycles of standard beacopp
    Indication: Hodgkin's Disease

Doxorubicin HCL
    Dosage: 25 mg/m2, for 4 cycles of standard beacopp
    Indication: Hodgkin's Disease

Doxorubicin HCL
    Dosage: 35 mg/m2, for 2 cycles of escalated beacopp

Procarbazine Hydrochloride
    Dosage: 700 mg/m2, for all 6 cycles of beacopp
    Indication: Hodgkin's Disease



 Page 1   Next >>

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014